AI-Enabled Eko Health Stethoscope TRICORDER Trial Marks Historic Leap in Early Heart Disease Detection

SAN FRANCISCO, Calif. – September 9, 2025 — Eko Health, a leader in AI-powered cardiac and pulmonary disease detection, today announced groundbreaking results from the TRICORDER (Triple Cardiovascular Disease Detection Using an Artificial Intelligence Smart Stethoscope) study, led by Imperial College London and Imperial College Healthcare NHS Trust.

One of the largest randomized evaluations of AI ever conducted in routine care, TRICORDER spanned 205 NHS GP practices with 1.5 million registered patients, including more than 12,800 AI-stethoscope exams performed by nearly 1,000 providers. Results showed that when Eko Health’s AI-enabled digital stethoscope was used as intended during routine exams, detection of major cardiac conditions increased dramatically over a 12-month period compared to the standard of care:

• Heart failure: 2.3x more likely to be detected
• Atrial fibrillation (AFib): 3.5x more likely to be detected
• Valvular heart disease: 1.9x more likely to be detected

These findings, presented at the European Society of Cardiology Congress in Madrid, have drawn strong interest from providers and patient groups and underscore the potential for earlier cardiac disease detection and treatment.

“This is an elegant example of how the humble stethoscope, invented more than 200 years ago, can be upgraded for the 21st century,” said Dr. Nicholas S. Peters, Professor of Cardiology and Director of the Health Impact Lab at Imperial College London. “By helping GPs identify heart disease in seconds, this technology offers patients earlier access to life-saving treatment, often before symptoms become severe. Demonstrating the benefits of real-world implementation of Eko’s device is the real impact of the TRICORDER programme and the mission of The Health Impact Lab.” 

Unlike tightly controlled efficacy studies, TRICORDER was designed to mirror real-world practice. Providers used the device as they would in routine care, without prescriptive oversight. The findings demonstrate that integration of AI at the point of care can uncover hidden cardiac conditions that might otherwise remain undiagnosed until hospitalization or emergency care.

“The TRICORDER trial confirms what providers worldwide have experienced firsthand. AI can turn a routine exam using a stethoscope into one of the most powerful early detection tools in medicine,” said Connor Landgraf, Co-Founder and CEO of Eko Health. “This is not about future promises; it’s about saving lives today by giving clinicians actionable insights within seconds.”

Using advanced sound technology and ECG sensors, Eko digital stethoscopes capture sounds and electrical signals from the heart, then transmit them to the cloud for AI analysis trained on tens of thousands of patients. The results are available instantly at the point of care.

With plans to expand use of Eko AI-enabled digital stethoscopes across practices in South London, Sussex, and Wales, TRICORDER marks a milestone moment in the adoption of AI-powered tools in everyday clinical care.

About Eko Health

Eko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes and ECG devices, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, with over 650,000 devices sold to providers globally, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California.

For more information about Eko Health, visit ekohealth.com. 

About Health Impact Lab at Imperial

Imperial’s Health Impact Lab turns evidence into everyday practice by applying implementation science and clinician leadership to move impactful innovations into routine patient care. Visit healthimpactlab.co.uk/ to learn more.

Media contact

Sam Moore
sam.moore@ekohealth.com

MKT-0003945